F10 and Stroke: In the ARISTOTLE (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation) study, the patients were younger than in the RE-LY (Randomized Evaluation of Long Term Anticoagulant Therapy) and ROCKET-AF (The Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)studies [6,7,8].